These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 19524688

  • 1. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway.
    Zheng R, Wang L, Fan J, Zhou Q.
    Cell Biol Int; 2009 Sep; 33(9):926-33. PubMed ID: 19524688
    [Abstract] [Full Text] [Related]

  • 2. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C.
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [Abstract] [Full Text] [Related]

  • 3. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD).
    Fischer DC, Jacoby U, Pape L, Ward CJ, Kuwertz-Broeking E, Renken C, Nizze H, Querfeld U, Rudolph B, Mueller-Wiefel DE, Bergmann C, Haffner D.
    Nephrol Dial Transplant; 2009 Jun; 24(6):1819-27. PubMed ID: 19176689
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
    Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY.
    Pathol Int; 2009 Jan; 59(1):19-27. PubMed ID: 19121088
    [Abstract] [Full Text] [Related]

  • 5. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2008 Jun 01; 14(11):3589-97. PubMed ID: 18519793
    [Abstract] [Full Text] [Related]

  • 6. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P, Mateo J.
    Oncogene; 2009 Jan 22; 28(3):313-24. PubMed ID: 18978810
    [Abstract] [Full Text] [Related]

  • 7. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.
    Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT.
    Cancer Res; 2003 Dec 01; 63(23):8451-60. PubMed ID: 14679009
    [Abstract] [Full Text] [Related]

  • 8. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
    Jin X, Jin HR, Lee D, Lee JH, Kim SK, Lee JJ.
    Eur J Pharmacol; 2008 Sep 11; 592(1-3):41-7. PubMed ID: 18639543
    [Abstract] [Full Text] [Related]

  • 9. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP.
    Brain; 2009 Jun 11; 132(Pt 6):1509-22. PubMed ID: 19416948
    [Abstract] [Full Text] [Related]

  • 10. Down-regulation of PKHD1 induces cell apoptosis through PI3K and NF-κB pathways.
    Sun L, Wang S, Hu C, Zhang X.
    Exp Cell Res; 2011 Apr 15; 317(7):932-40. PubMed ID: 21300060
    [Abstract] [Full Text] [Related]

  • 11. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
    Böhm A, Aichberger KJ, Mayerhofer M, Herrmann H, Florian S, Krauth MT, Derdak S, Samorapoompichit P, Sonneck K, Vales A, Gleixner KV, Pickl WF, Sperr WR, Valent P.
    Eur J Clin Invest; 2009 May 15; 39(5):395-405. PubMed ID: 19320940
    [Abstract] [Full Text] [Related]

  • 12. Activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway.
    Dayan F, Bilton RL, Laferrière J, Trottier E, Roux D, Pouyssegur J, Mazure NM.
    J Cell Physiol; 2009 Jan 15; 218(1):167-74. PubMed ID: 18781596
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 15; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD).
    Sweeney WE, Avner ED.
    Cell Tissue Res; 2006 Dec 15; 326(3):671-85. PubMed ID: 16767405
    [Abstract] [Full Text] [Related]

  • 18. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease.
    Edelstein CL.
    Clin J Am Soc Nephrol; 2008 Jul 15; 3(4):1219-26. PubMed ID: 18587045
    [Abstract] [Full Text] [Related]

  • 19. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
    Janus A, Robak T, Smolewski P.
    Cell Mol Biol Lett; 2005 Jul 15; 10(3):479-98. PubMed ID: 16217558
    [Abstract] [Full Text] [Related]

  • 20. Regulation of cell proliferation and apoptosis through fibrocystin-prosaposin interaction.
    Sun L, Wang S, Hu C, Zhang X.
    Arch Biochem Biophys; 2010 Oct 15; 502(2):130-6. PubMed ID: 20709014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.